{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Adverse effects", "complications", "coronavirus disease 2019", "disease management", "heart"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36685029", "DateRevised": {"Year": "2023", "Month": "01", "Day": "24"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "12", "Day": "23"}], "Language": ["eng"], "ELocationID": ["92", "10.4103/jrms.jrms_895_21"], "Journal": {"ISSN": "1735-1995", "JournalIssue": {"Volume": "27", "PubDate": {"Year": "2022"}}, "Title": "Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences", "ISOAbbreviation": "J Res Med Sci"}, "ArticleTitle": "Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns.", "Pagination": {"StartPage": "92", "MedlinePgn": "92"}, "Abstract": {"AbstractText": ["Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has rapidly spread worldwide and has been infected more than 219 million individuals with 4.55 million deaths worldwide as of September 2021, causing a pandemic. Preexisting cardiovascular (CV) comorbidities such as hypertension, diabetes, and coronary artery disease seem to be associated with greater severity of infection, worse prognosis, and higher mortality. Moreover, COVID-19 can contribute to CV complications, including acute myocardial injury, arrhythmia, acute coronary syndrome, and venous thromboembolism, emphasizing the importance of precocious detection and implementation of optimal therapeutic strategies. This review provides an overview of evidence-based data of CV complications of COVID-19, focusing on their management strategies, as well as potential cardiac adverse effects and drug interactions, due to off-label and investigational drugs used for the treatment of COVID-19."], "CopyrightInformation": "Copyright: \u00a9 2022 Journal of Research in Medical Sciences."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran."}], "LastName": "Hamidian", "ForeName": "Maliheh", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Ansari", "ForeName": "Ramin", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran."}, {"Identifier": [], "Affiliation": "Department of Phytopharmaceuticals (Traditional Pharmacy), School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran."}], "LastName": "Zarshenas", "ForeName": "Mohammad Mehdi", "Initials": "MM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran."}], "LastName": "Foroughinia", "ForeName": "Farzaneh", "Initials": "F"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "India", "MedlineTA": "J Res Med Sci", "NlmUniqueID": "101235599", "ISSNLinking": "1735-1995"}, "CoiStatement": "There are no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Allergy Clin Immunol. 2020;146:110\u20138.", "ArticleIdList": ["PMC7152876", "32294485"]}, {"Citation": "Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158:1831\u20133.e3.", "ArticleIdList": ["PMC7130181", "32142773"]}, {"Citation": "Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020;323:1061\u20139.", "ArticleIdList": ["PMC7042881", "32031570"]}, {"Citation": "Ziyaeifard M, Ziyaeifard P. Cardiac anesthesia and COVID-19 outbreak: What should we know? J Res Med Sci. 2020;25:89.", "ArticleIdList": ["PMC7698443", "33273934"]}, {"Citation": "Nayeri ND, Nadali J, Divani A, Basirinezhad MH, Meidani M. Clinical manifestation, laboratory and radiology finding, treatment and outcomes of COVID-19: A systematic review and meta-analysis. J Res Med Sci. 2021;26:41.", "ArticleIdList": ["PMC8383992", "34484373"]}, {"Citation": "Hajhossein Talasaz A, Kakavand H, Van Tassell B, Aghakouchakzadeh M, Sadeghipour P, Dunn S, et al. Cardiovascular complications of COVID-19: Pharmacotherapy perspective. Cardiovasc Drugs Ther. 2021;35:249\u201359.", "ArticleIdList": ["PMC7360896", "32671601"]}, {"Citation": "Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020;382:2327\u201336.", "ArticleIdList": ["PMC7169476", "32275812"]}, {"Citation": "Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 \u2013 Final report. N Engl J Med. 2020;383:1813\u201326.", "ArticleIdList": ["PMC7262788", "32445440"]}, {"Citation": "Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585:273\u20136.", "ArticleIdList": ["PMC7486271", "32516797"]}, {"Citation": "Touafchia A, Bagheri H, Carri\u00e9 D, Durrieu G, Sommet A, Chouchana L, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): A new safety concerns. Clin Microbiol Infect. 2021;27:791.e5\u20138.", "ArticleIdList": ["PMC7910147", "33647441"]}, {"Citation": "Falzarano D, De Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel \u03b2 coronavirus replication by a combination of interferon-\u03b12b and ribavirin. Sci Rep. 2013;3:1\u20136.", "ArticleIdList": ["PMC3629412", "23594967"]}, {"Citation": "Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. Ribavirin therapy for severe COVID-19: A retrospective cohort study. Int J Antimicrob Agents. 2020;56:106114.", "ArticleIdList": ["PMC7377772", "32712334"]}, {"Citation": "Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382:1787\u201399.", "ArticleIdList": ["PMC7121492", "32187464"]}, {"Citation": "Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. Lancet. 2020;395:1695\u2013704.", "ArticleIdList": ["PMC7211500", "32401715"]}, {"Citation": "Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: A review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020;9:215\u201321.", "ArticleIdList": ["PMC7235441", "32372695"]}, {"Citation": "Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care. 2020;24:1\u20133.", "ArticleIdList": ["PMC7347251", "32646499"]}, {"Citation": "Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E. QTc interval prolongation during favipiravir therapy in an Ebola virus-infected patient. PLoS Negl Trop Dis. 2017;11:e0006034.", "ArticleIdList": ["PMC5746205", "29283993"]}, {"Citation": "Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: Inhibition by 239 drugs. J Clin Pharmacol. 2004;44:7\u201319.", "ArticleIdList": ["14681337"]}, {"Citation": "Schluenz LA, Ramos-Otero GP, Nawarskas JJ. Chloroquine or hydroxychloroquine for management of coronavirus disease 2019: Friend or foe? Cardiol Rev. 2020;28:266\u201371.", "ArticleIdList": ["32769401"]}, {"Citation": "Elavarasi A, Prasad M, Seth T, Sahoo RK, Madan K, Nischal N, et al. Chloroquine and hydroxychloroquine for the treatment of COVID-19: A systematic review and meta-analysis. J Gen Intern Med. 2020;35:3308\u201314.", "ArticleIdList": ["PMC7471562", "32885373"]}, {"Citation": "Monzani A, Genoni G, Scopinaro A, Pistis G, Kozel D, Secco GG. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine. Eur J Clin Invest. 2020;50:e13258.", "ArticleIdList": ["PMC7235515", "32356580"]}, {"Citation": "Kapoor A, Pandurangi U, Arora V, Gupta A, Jaswal A, Nabar A, et al. Reply to letters regarding our paper \u201cCardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society\u201d. Indian Pacing Electrophysiol J. 2020;20:209\u201310.", "ArticleIdList": ["PMC7347489", "32653526"]}, {"Citation": "Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. 2020;6:56\u201370.", "ArticleIdList": ["PMC7211915", "32395418"]}, {"Citation": "Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:384.", "ArticleIdList": ["PMC7195369", "32240719"]}, {"Citation": "Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17:1425\u201333.", "ArticleIdList": ["PMC7214283", "32407884"]}, {"Citation": "Fohner AE, Sparreboom A, Altman RB, Klein TE. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2017;27:164\u20137.", "ArticleIdList": ["PMC5346035", "28146011"]}, {"Citation": "Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.", "ArticleIdList": ["PMC7270045", "32192578"]}, {"Citation": "Menzella F, Fontana M, Salvarani C, Massari M, Ruggiero P, Scelfo C, et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020;24:1\u20139.", "ArticleIdList": ["PMC7523258", "32993751"]}, {"Citation": "Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: A multicentre observational study. Lancet Rheumatol. 2020;2:e603\u201312.", "ArticleIdList": ["PMC7428303", "32838323"]}, {"Citation": "Solis-Garc\u00eda Del Pozo J, Galindo MF, Nava E, Jord\u00e1n J. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients. Eur Rev Med Pharmacol Sci. 2020;24:7475\u201384.", "ArticleIdList": ["32706087"]}, {"Citation": "Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592\u20139.", "ArticleIdList": ["27438459"]}, {"Citation": "Zhang X, Zhang Y, Qiao W, Zhang J, Qi Z. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol. 2020;86:106749.", "ArticleIdList": ["PMC7328558", "32645632"]}, {"Citation": "Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2020;384:795\u2013807.", "ArticleIdList": ["PMC7745180", "33306283"]}, {"Citation": "Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Can\u00e8 S, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130:6409\u201316.", "ArticleIdList": ["PMC8016181", "32809969"]}, {"Citation": "Assadiasl S, Fatahi Y, Mosharmovahed B, Mohebbi B, Nicknam MH. Baricitinib: From rheumatoid arthritis to COVID-19. J Clin Pharmacol. 2021;61:1274\u201385.", "ArticleIdList": ["PMC8250677", "33870531"]}, {"Citation": "Ferra\u00f9 F, Ceccato F, Cannav\u00f2 S, Scaroni C. What we have to know about corticosteroids use during Sars-Cov-2 infection. J Endocrinol Invest. 2021;44:693\u2013701.", "ArticleIdList": ["PMC7454136", "32860209"]}, {"Citation": "Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693\u2013704.", "ArticleIdList": ["PMC7383595", "32678530"]}, {"Citation": "Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W, Rochwerg B, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: A systematic review and meta-analysis. CMAJ. 2020;192:E755\u201367.", "ArticleIdList": ["PMC7828900", "32409522"]}, {"Citation": "Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. J Am Med Assoc. 2020;324:1330\u201341.", "ArticleIdList": ["PMC7489434", "32876694"]}, {"Citation": "Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: Review and assessment. Eur Rev Med Pharmacol Sci. 2020;24:12593\u2013608.", "ArticleIdList": ["33336780"]}, {"Citation": "Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033\u201340.", "ArticleIdList": ["PMC7273827", "32339221"]}, {"Citation": "Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18:1020\u20132.", "ArticleIdList": ["PMC9906146", "32239799"]}, {"Citation": "Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148\u201350.", "ArticleIdList": ["PMC7192101", "32381264"]}, {"Citation": "Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094\u20139.", "ArticleIdList": ["PMC9906401", "32220112"]}, {"Citation": "Abdel-Maboud M, Menshawy A, Elgebaly A, Bahbah EI, Ashal GE, Negida A. Should we consider heparin prophylaxis in COVID-19 patients? A systematic review and meta-analysis. Thromb Thrombolysis. 2020;51:830\u20132.", "ArticleIdList": ["PMC7439245", "32816197"]}, {"Citation": "Preliminary Experience with Low Molecular Weight Heparin Strategy in COVID-19 Patients | Enhanced Reader.  [Last accessed on 2021 May 01].  Available from: https://chrome-extension://mbcgpelmjnpfbdnkbebdlfjmeckpnhha/enhanced-reader.html ?pdf=https%3A%2F%2Fbrxt.mendeley.com%2Fdocument%2Fcontent%2Fe69be289-ed5c-3008-85b7-21cb91330bef ."}, {"Citation": "Mattioli M, Benfaremo D, Mancini M, Mucci L, Mainqu\u00e0 P, Polenta A, et al. Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. Thromb Thrombolysis. 2020;51:286\u201392.", "ArticleIdList": ["PMC7426007", "32794132"]}, {"Citation": "Kartsios C, Lokare A, Osman H, Perrin D, Razaq S, Ayub N, et al. Diagnosis, management, and outcomes of venous thromboembolism in COVID-19 positive patients: A role for direct anticoagulants? J Thromb Thrombolysis. 2021;51:947\u201352.", "ArticleIdList": ["PMC7481340", "32910408"]}, {"Citation": "Testa S, Prandoni P, Paoletti O, Morandini R, Tala M, Dellanoce C, et al. Direct oral anticoagulant plasma levels\u2019 striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost. 2020;18:1320\u20133.", "ArticleIdList": ["PMC7264501", "32329231"]}, {"Citation": "Kow CS, Sunter W, Bain A, Zaidi ST, Hasan SS. Management of outpatient warfarin therapy amid COVID-19 pandemic: A practical guide. Am J Cardiovasc Drugs. 2020;20:301\u20139.", "ArticleIdList": ["PMC7247959", "32458370"]}, {"Citation": "Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and standardization committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1859\u201365.", "ArticleIdList": ["PMC7283841", "32459046"]}, {"Citation": "Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: Interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020;50:72\u201381.", "ArticleIdList": ["PMC7241581", "32440883"]}, {"Citation": "Kipshidze N, Dangas G, White CJ, Kipshidze N, Siddiqui F, Lattimer CR, et al. Viral coagulopathy in patients with COVID-19: Treatment and care. Clin Appl Thromb Hemost. 2020;26:107602962093677.", "ArticleIdList": ["PMC7461127", "32687449"]}, {"Citation": "Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2950\u201373.", "ArticleIdList": ["PMC7164881", "32311448"]}, {"Citation": "Vadukul P, Sharma DS, Vincent P. Massive pulmonary embolism following recovery from COVID-19 infection: Inflammation, thrombosis and the role of extended thromboprophylaxis. BMJ Case Rep. 2020;13:238168.", "ArticleIdList": ["PMC7488789", "32928824"]}, {"Citation": "Akel T, Qaqa F, Abuarqoub A, Shamoon F. Pulmonary embolism: A complication of COVID 19 infection. Thromb Res. 2020;193:79\u201382.", "ArticleIdList": ["PMC7247481", "32526545"]}, {"Citation": "Ali S, Mathew S, Pappachan JM. Acute cor pulmonale from saddle pulmonary embolism in a patient with previous COVID-19: Should we prolong prophylactic anticoagulation? Int J Infect Dis. 2020;97:299\u2013302.", "ArticleIdList": ["PMC7293501", "32544670"]}, {"Citation": "Arachchillage DJ, Stacey A, Akor F, Scotz M, Laffan M. Thrombolysis restores perfusion in COVID-19 hypoxia. Br J Haematol. 2020;190:e270\u20134.", "ArticleIdList": ["PMC7436762", "32735730"]}, {"Citation": "Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost. 2020;18:1752\u20135.", "ArticleIdList": ["PMC7262152", "32267998"]}, {"Citation": "Stevenson A, Davis S, Murch N. Pulmonary embolism in acute medicine: A case-based review incorporating latest guidelines in the COVID-19 era. Br J Hosp Med (Lond) 2020;81:1\u201312.", "ArticleIdList": ["32589531"]}, {"Citation": "Nawazani A, Ghanaim M, Tariq S. Case of COVID-19 infection and polycythaemia presenting with massive acute pulmonary embolism. BMJ Case Rep. 2020;13:237390.", "ArticleIdList": ["PMC7511615", "32948531"]}, {"Citation": "Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020;18:1548\u201355.", "ArticleIdList": ["PMC7264738", "32329246"]}, {"Citation": "Cheung CC, Davies B, Gibbs K, Laksman ZW, Krahn AD. Multilead QT screening is necessary for QT measurement: Implications for management of patients in the COVID-19 Era. JACC Clin Electrophysiol. 2020;6:878\u201380.", "ArticleIdList": ["PMC7141442", "32703574"]}, {"Citation": "Sacher F, Fauchier L, Boveda S, de Chillou C, Defaye P, Deharo JC, et al. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection. Arch Cardiovasc Dis. 2020;113:293\u20136.", "ArticleIdList": ["PMC7180362", "32354666"]}, {"Citation": "Roden DM, Harrington RA, Poppas A, Russo AM, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 treatment. Circulation. 2020;141:E906\u20137.", "ArticleIdList": ["32267732"]}, {"Citation": "Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19) Mayo Clin Proc. 2020;95:1213\u201321.", "ArticleIdList": ["PMC7141471", "32359771"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "10", "Day": "10"}, {"Year": "2022", "Month": "5", "Day": "30"}, {"Year": "2022", "Month": "6", "Day": "13"}, {"Year": "2023", "Month": "1", "Day": "23", "Hour": "4", "Minute": "30"}, {"Year": "2023", "Month": "1", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "24", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "12", "Day": "23"}], "PublicationStatus": "epublish", "ArticleIdList": ["36685029", "PMC9854922", "10.4103/jrms.jrms_895_21", "JRMS-27-92"]}}], "PubmedBookArticle": []}